Literature DB >> 11676995

A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients.

C E Jackson1, J Rosenfeld, D H Moore, W W Bryan, R J Barohn, M Wrench, D Myers, L Heberlin, R King, J Smith, D Gelinas, R G Miller.   

Abstract

There is still no consensus as to which physiologic marker should be used as a trigger for the initiation of non-invasive positive pressure ventilation (NPPV) in patients with amyotrophic lateral sclerosis (ALS). Current practice parameters recommend that the decision to begin treatment be based upon forced vital capacity (FVC) measurements. A prospective, randomized study was performed in 20 ALS patients who had an FVC of 70-100%. Patients received baseline assessments including: ALS functional rating scale-respiratory version (ALSFRS-R), pulmonary symptom scale, Short form 36 (SF-36), FVC%, maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), and nocturnal oximetry. Patients were randomized to receive NPPV based upon nocturnal oximetry studies suggesting oxygen desaturation <90% for one cumulative minute ("early intervention") or a FVC <50% ("standard of care"). At enrollment, there was no significant correlation between FVC% and the ALSFRS-R, symptom score, MEP, MIP, or duration of nocturnal desaturation <90%. An increase in the vitality subscale of the SF-36 was demonstrated in 5/6 patients randomized to "early intervention" with NPPV. Our data indicate that FVC% correlates poorly with respiratory symptoms and suggests that MIP and nocturnal oximetry may be more sensitive measures of early respiratory insufficiency. In addition, intervention with NPPV earlier than our current standard of care may result in improved quality of life.

Entities:  

Mesh:

Year:  2001        PMID: 11676995     DOI: 10.1016/s0022-510x(01)00617-7

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  32 in total

1.  Home mechanical ventilation: a Canadian Thoracic Society clinical practice guideline.

Authors:  Douglas A McKim; Jeremy Road; Monica Avendano; Steve Abdool; Fabien Cote; Nigel Duguid; Janet Fraser; Fracois Maltais; Debra L Morrison; Colleen O'Connell; Basil J Petrof; Karen Rimmer; Robert Skomro
Journal:  Can Respir J       Date:  2011 Jul-Aug       Impact factor: 2.409

2.  Evaluation and management of pulmonary disease in ataxia-telangiectasia.

Authors:  Sharon A McGrath-Morrow; W Adam Gower; Cynthia Rothblum-Oviatt; Alan S Brody; Claire Langston; Leland L Fan; Maureen A Lefton-Greif; Thomas O Crawford; Michelle Troche; John T Sandlund; Paul G Auwaerter; Blaine Easley; Gerald M Loughlin; John L Carroll; Howard M Lederman
Journal:  Pediatr Pulmonol       Date:  2010-09

3.  Management of symptoms in amyotrophic lateral sclerosis.

Authors:  Lisa S Thibodeaux; Amparo Gutierrez
Journal:  Curr Treat Options Neurol       Date:  2008-03       Impact factor: 3.598

4.  Amyotrophic lateral sclerosis: clinical management and research update.

Authors:  Jinsy Andrews
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

Review 5.  Amyotrophic lateral sclerosis: update for family physicians.

Authors:  Christen L Shoesmith; Michael J Strong
Journal:  Can Fam Physician       Date:  2006-12       Impact factor: 3.275

Review 6.  Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis.

Authors:  Carlayne E Jackson; April L McVey; Stacy Rudnicki; Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

7.  Respiratory and nutritional support in amyotrophic lateral sclerosis.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2014-02       Impact factor: 3.598

Review 8.  Nocturnal hypoventilation in neuromuscular disease: prevalence according to different definitions issued from the literature.

Authors:  Adam Ogna; Maria-Antonia Quera Salva; Helene Prigent; Ghassane Mroue; Isabelle Vaugier; Djillali Annane; Frederic Lofaso; David Orlikowski
Journal:  Sleep Breath       Date:  2015-09-04       Impact factor: 2.816

9.  Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population.

Authors:  A Czaplinski; A A Yen; S H Appel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

10.  Early treatment with noninvasive positive pressure ventilation prolongs survival in Amyotrophic Lateral Sclerosis patients with nocturnal respiratory insufficiency.

Authors:  Pierluigi Carratù; Lucia Spicuzza; Anna Cassano; Mauro Maniscalco; Felice Gadaleta; Donato Lacedonia; Cristina Scoditti; Ester Boniello; Giuseppe Di Maria; Onofrio Resta
Journal:  Orphanet J Rare Dis       Date:  2009-03-10       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.